CHICAGO – Esya Labs, which is developing several ground-breaking novel research assays, today has announced that Novartis is among the first companies to use its technology. Novartis, a global healthcare company, has used a patented assay developed by Esya Labs to accelerate drug discovery efforts for Mucolipidosis Type IV, a rare inherited metabolic...
Latest News
Zurich, Switzerland – Glioblastoma is a particularly aggressive brain tumour that at present is incurable. Cancer doctors can extend patients’ life expectancy through operations, radiation, chemotherapy or surgical interventions. Nevertheless, half of patients die within twelve months of diagnosis. Drugs that are effective against brain tumours are difficult to find,...
DEER PARK, Ill. — Eton Pharmaceuticals (Nasdaq: ETON), an innovative pharmaceutical company focused on developing, acquiring, and commercializing products to address unmet needs in patients suffering from rare diseases, today announced the commercial availability of Nitisinone Capsules for the treatment of hereditary tyrosinemia type 1 (HT-1) in combination with dietary...
Brussels, Belgium – Multiple sclerosis (MS), an inflammatory disease of the central nervous system, affects more than 1 million people in Europe and an estimated 2.8 million worldwide. MS is characterized by an inflammation-related loss and damage of the myelin layer in the brain and spinal cord, which insulates the...
A group of more than 40 EU lawmakers backed the idea of an EU action plan for rare diseases, in a letter addressed to European Commission President Ursula von der Leyen.
VICTORIA, British Columbia — Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced the first patient dosed in the Phase 2b randomized, placebo-controlled portion of the...
EMERYVILLE, Calif. – Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T-cell therapies to treat solid tumors, today announced the initiation of ARYA-2, a Phase I/II open-label, dose escalation clinical trial of ET140203 ARTEMIS® T-cell therapy in pediatric patients with relapsed or refractory hepatoblastoma (HB), hepatocellular neoplasm not otherwise specified (HCN-NOS),...
EMERYVILLE, Calif. – Eureka Therapeutics, Inc. announced today that Eureka and Memorial Sloan Kettering Cancer Center (MSK) entered into a license agreement with Sanofi for the non-CAR use of a novel, human binding domain targeting GPRC5D (G Protein-Coupled Receptor Family C Group 5 Member D). The GPRC5D binding domain was discovered using...
BRIDGEWATER, N.J. — Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that the European Commission has approved BRINSUPRI (brensocatib 25 mg tablets) for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in...
Beerse, Belgium — Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the European Commission (EC) has approved a new indication for DARZALEX® (daratumumab) subcutaneous (SC) formulation as monotherapy for the treatment of adult patients with smouldering multiple myeloma (SMM) at high-risk of developing multiple myeloma.3 SMM is an...